日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis

在针对中重度银屑病患者的IIb期研究中,Icotrokinra可诱导早期且持续的药效学反应。

Strawn, David; Krueger, James G; Bissonnette, Robert; Eyerich, Kilian; Ferris, Laura K; Paller, Amy S; Pinter, Andreas; Richards, Dylan; Chen, Elizabeth Y; Paget, Kate; Horowitz, Daniel; Parast, Roohid; Rusbuldt, Joshua J; Sendecki, Jocelyn; Bhagat, Sunita; Tomsho, Lynn P; Chou, Ching-Heng; Polak, Marta E; Keyes, Brice E; Bozenhardt, Emily; Xiong, Yuan; Zhou, Wangda; DeKlotz, Cynthia; Newbold, Paul; Waterworth, Dawn M; Miller, Megan; Ota, Takayuki; Yang, Ya-Wen; Leung, Monica Wl; Miller, Lloyd S; Cuff, Carolyn A; McRae, Bradford; Ruane, Darren; Kannan, Arun K

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study

波兰国家注册中心使用 Brolucizumab、Aflibercept 和 Ranibizumab 治疗 nAMD 的 12 个月抗 VEGF 疗法疗效:一项多中心数据库研究

Teper, Sławomir; Ledwoń, Daniel; Romaniszyn-Kania, Patrycja; Sendecki, Adam; Tuszy, Aleksandra; Nycz, Julia; Mitas, Andrzej W; Figurska, Małgorzata; Wylęgała, Edward; Rękas, Marek

Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial

在银屑病超级应答者中,16 周与 8 周古塞库单抗给药方案在维持病情控制方面不劣于其他方案:GUIDE 随机临床试验

Eyerich, Kilian; Asadullah, Khusru; Pinter, Andreas; Weisenseel, Peter; Reich, Kristian; Paul, Carle; Sabat, Robert; Wolk, Kerstin; Eyerich, Stefanie; Lauffer, Felix; Angsana, Julianty; Taut, Friedemann J H; Kohler, Kristen; Chen, Yanqing; Sendecki, Jocelyn; Leung, Monica W L; Wegner, Sven; Personke, Yvonne; Gomez, Mario; Krüger, Nenja; Tabori, Sarah; Schäkel, Knut

Fundus Image Deep Learning Study to Explore the Association of Retinal Morphology with Age-Related Macular Degeneration Polygenic Risk Score

眼底图像深度学习研究旨在探索视网膜形态与年龄相关性黄斑变性多基因风险评分之间的关联

Sendecki, Adam; Ledwoń, Daniel; Tuszy, Aleksandra; Nycz, Julia; Wąsowska, Anna; Boguszewska-Chachulska, Anna; Mitas, Andrzej W; Wylęgała, Edward; Teper, Sławomir

Association of Genetic Risk for Age-Related Macular Degeneration with Morphological Features of the Retinal Microvascular Network

年龄相关性黄斑变性遗传风险与视网膜微血管网络形态特征的关联

Sendecki, Adam; Ledwoń, Daniel; Tuszy, Aleksandra; Nycz, Julia; Wąsowska, Anna; Boguszewska-Chachulska, Anna; Wylęgała, Adam; Mitas, Andrzej W; Wylęgała, Edward; Teper, Sławomir

Polygenic Risk Score and Rare Variant Burden Identified by Targeted Sequencing in a Group of Patients with Pigment Epithelial Detachment in Age-Related Macular Degeneration

通过靶向测序鉴定年龄相关性黄斑变性伴色素上皮脱离患者的多基因风险评分和罕见变异负荷

Wąsowska, Anna; Sendecki, Adam; Boguszewska-Chachulska, Anna; Teper, Sławomir

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models

在人类癌症模型中发现并进行抗程序性细胞死亡蛋白-1 (PD-1) 抗体西曲利单抗 (JNJ-63723283) 的药理学表征

Nikki DeAngelis # ,Catherine Ferrante # ,Gordon Powers ,Jocelyn Sendecki ,Bethany Mattson ,Darlene Pizutti ,Kathryn Packman ,Weirong Wang ,Kevin Trouba ,Rupesh Nanjunda ,John Wheeler ,Ray Brittingham ,Sheng-Jiun Wu ,Jinquan Luo ,Matthew V Lorenzi ,Raluca I Verona

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma

CD38抗体在多发性骨髓瘤中的体外和离体作用机制比较

Kinder, Michelle; Bahlis, Nizar J; Malavasi, Fabio; De Goeij, Bart; Babich, Alexander; Sendecki, Jocelyn; Rusbuldt, Joshua; Bellew, Kevin; Kane, Colleen; Van de Donk, Niels W C J

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

GPRC5DxCD3双特异性抗体talquetamab在多发性骨髓瘤中的临床前活性和反应决定因素

Verkleij, Christie P M; Broekmans, Marloes E C; van Duin, Mark; Frerichs, Kristine A; Kuiper, Rowan; de Jonge, A Vera; Kaiser, Martin; Morgan, Gareth; Axel, Amy; Boominathan, Rengasamy; Sendecki, Jocelyn; Wong, Amy; Verona, Raluca I; Sonneveld, Pieter; Zweegman, Sonja; Adams, Homer C; Mutis, Tuna; van de Donk, Niels W C J

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Amivantamab (JNJ-61186372) 是一种 Fc 增强型 EGFR/cMet 双特异性抗体,通过单核细胞/巨噬细胞吞噬作用诱导受体下调和抗肿瘤活性

Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Sendecki, Marilda Beqiri, Hillary J Millar, Kathryn Packman, Matthew V Lorenzi, Sylvie Laquerre, Sheri L Moores